Lightchain Capital

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making in complex environments. Founded in 2018, the company offers solutions that optimize and accelerate processes such as scheduling, production planning, and portfolio optimization. By leveraging advanced algorithmic innovations, SimpleRose’s platform provides high levels of numerical accuracy, speed, and the capability for continuous analysis, enabling organizations to effectively address operational challenges and make informed decisions.

AI Proteins is a biotechnology company established in 2021 and based in Boston, Massachusetts. The company specializes in the design and engineering of synthetic mini protein therapeutics, utilizing an innovative drug discovery platform that re-structures protein therapeutics. By employing artificial intelligence, AI Proteins creates synthetic proteins from scratch, optimizing their activity for various therapeutic applications. This approach accelerates the development of lead product candidates, allowing clients access to cost-effective, durable, and specific proteins that can be optimized for oral delivery.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making in complex environments. Founded in 2018, the company offers solutions that optimize and accelerate processes such as scheduling, production planning, and portfolio optimization. By leveraging advanced algorithmic innovations, SimpleRose’s platform provides high levels of numerical accuracy, speed, and the capability for continuous analysis, enabling organizations to effectively address operational challenges and make informed decisions.